November 14, 2001 Flamel Technologies announces funded feasibilty study with a major bio-pharmaceutical company using its Medusa® technology.

October 30, 2001 Flamel Technologies announces third quarter results, loss per share of $(0.04).

October 23, 2001 Flamel Technologies S.A. announces completion of human proof of concept study for controlled-release antibiotic.

October 10, 2001 Flamel Technologies announces licensing agreement with Merck & Co., Inc..

September 27, 2001 Flamel Technologies announces negative response of French authorities on filing of Genvir® for registration.

August 24, 2001 Flamel Technologies announces the resignation of Jean Deleage as a board member.

July 30, 2001 Flamel Technologies announces second quarter and first half of 2001.

July 12, 2001 Flamel Technologies announces a feasibility study employing Medusa®; positive phase I results with Micropump ® and departure of Michael Myers.

April 30, 2001 Flamel Technologies announces first quarter results, reducing loss per share to $(0.05) on higher revenues.

March 15, 2001 Flamel Technologies announces 2000 results

January 10, 2001 Flamel Technologies announces two new Micropump® feasability studies with major pharmaceutical companies, change to NASDAQ trading symbol

January 4, 2001 Flamel Technologies to work with Connetics Corporation on new feasability study utilizing Medusa®, Flamel's patented protein delivery technology